Loading…
Lipocine Inc. is projected to rise to $3.23 by 2027, a +34% move from its current price of $2.41. LPCN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $2.34 | $2.41 | $2.48 | +0.02% |
| Jul 13 | $2.32 | $2.41 | $2.51 | +0.03% |
| Jul 14 | $2.30 | $2.41 | $2.53 | +0.05% |
| Jul 15 | $2.28 | $2.41 | $2.55 | +0.06% |
| Jul 16 | $2.26 | $2.41 | $2.57 | +0.08% |
| Jul 17 | $2.25 | $2.41 | $2.59 | +0.10% |
| Jul 18 | $2.24 | $2.41 | $2.60 | +0.11% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.24 | $2.41 | $2.60 | +0.11% |
| Week 2 | $2.17 | $2.42 | $2.69 | +0.22% |
| Week 3 | $2.12 | $2.42 | $2.75 | +0.34% |
| Week 4 | $2.08 | $2.42 | $2.81 | +0.45% |
| Week 5 | $2.05 | $2.42 | $2.87 | +0.56% |
| Week 6 | $2.02 | $2.43 | $2.92 | +0.67% |
| Week 7 | $1.99 | $2.43 | $2.96 | +0.79% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Lipocine Inc. is a clinical-stage biopharmaceutical company focused on research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy comprising testosterone undecanoate, and is developing multiple other therapies across CNS disorders, liver disease, and hormone supplementation, including LPCN 1154 (BRLIZIO) for postpartum depression, LPCN 1148 for decompensated cirrhosis, LPCN 1107 for prevention of recurrent preterm birth, LPCN 1144 for pre-cirrhotic non-alcoholic steatohepatitis, LPCN 2401 for obesity management, and LPCN 2201, LPCN 2203, and LPCN 2101.
Lipocine was founded in 1997 and is headquartered in Salt Lake City, Utah. It has a collaboration with Verity Pharmaceuticals, Inc. to develop and commercialize TLANDO, and TLANDO XR (LPCN 1111), a once-daily oral product candidate that has completed a Phase 2 trial for testosterone replacement therapy.
Lipocine Inc. (LPCN) is a Healthcare sector company with a current price of $2.53 per share. It has a market capitalization of $20.86M and ranks 4912 by market cap. The price outlook reflected in the forecast is bullish over the longer term, with the average price rising to higher levels through 2030 and beyond.
The 2026 average is $2.53, and the 2030 average is $4.78, rising further to $13.40 by 2040 and $24.75 by 2050, with corresponding ROIs of 89.1, 429.5, and 878.2 respectively. Near term, sentiment remains supportive, and the 30-day picture suggests upside potential against defined support and resistance levels.
A major floor 27.9% below — a decisive break under it would weaken the trend.
The nearest floor, 17.8% below — buyers have tended to step in here.
The nearest ceiling, 6.2% above — a clean break opens room to run.
A major ceiling 283.8% above — clearing it would confirm fresh momentum.
Key LPCN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LPCN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.45 | Sell | $2.44 | Sell |
| MA 10 | $2.46 | Sell | $2.44 | Sell |
| MA 20 | $2.40 | Buy | $2.40 | Buy |
| MA 50 | $2.31 | Buy | $2.71 | Sell |
| MA 100 | $4.24 | Sell | $3.54 | Sell |
| MA 200 | $4.65 | Sell | $4.11 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 49.82 | Neutral |
| Stoch RSI (14) | 24.28 | Neutral |
| CCI (20) | 7.68 | Neutral |
| Williams %R (14) | -55.56 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | -4.74 | Sell |
| Bollinger %B (20,2) | 0.52 | Neutral |
| Stochastic %K (14) | 44.44 | Neutral |
| TRIX (15) | 0.19 | Buy |
| Awesome (5,34) | 0.14 | Buy |
| Ultimate (7,14,28) | 40.24 | Neutral |
| Momentum (10) | 0.03 | Buy |
| Aroon Osc (25) | 52.00 | Buy |
| Hull MA (9) | 2.44 | Sell |
| ADX (14) | 13.54 | Neutral |
| ATR (14) | 0.06 | Info |
The 30-day technical picture is bullish, with RSI14 at 60. The stock trades around the $2.53 area, with a 50-day simple moving average (SMA) at $2.30 and a 200-day SMA at $4.67. Near-term resistance is at $2.53 and support sits at $1.98.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.94 | $2.41 | $3.14 | 0% | Neutral | |
| $2.56 | $3.23 | $4.31 | +34% | Bullish | |
| $2.94 | $3.82 | $5.30 | +59% | Bullish | |
| $3.12 | $4.15 | $5.94 | +72% | Bullish | |
| $3.16 | $4.29 | $6.30 | +78% | Bullish | |
| $3.38 | $4.68 | $7.01 | +94% | Bullish | |
| $3.50 | $4.94 | $7.55 | +105% | Bullish | |
| $3.95 | $5.66 | $8.81 | +135% | Bullish | |
| $4.83 | $7.04 | $11.13 | +192% | Bullish | |
| $5.10 | $7.56 | $12.13 | +214% | Bullish | |
| $7.03 | $11.18 | $19.13 | +364% | Bullish | |
| $11.26 | $20.24 | $37.98 | +740% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.94 | $2.41 | $2.86 | +0.00% |
| August 2026 | $2.00 | $2.37 | $2.87 | -1.84% |
| September 2026 | $2.05 | $2.45 | $3.00 | +3.37% |
| October 2026 | $2.09 | $2.51 | $3.11 | +2.47% |
| November 2026 | $2.04 | $2.46 | $3.08 | -1.82% |
| December 2026 | $2.06 | $2.50 | $3.14 | +1.43% |
Click any year to see its month-by-month LPCN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, LPCN could reach as high as $3.14, with a base case around $2.41 and support toward $1.94 — roughly 0% from $2.41. Price action looks broadly range-bound.
Expect LPCN to range from $2.56 to $4.31 through 2027. The $3.23 average target implies a +34% move from current prices. That is up +34% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The LPCN price prediction for 2028 points to an average of $3.82 (low $2.94, high $5.30) — a potential gain of +59% on today's $2.41. Momentum favours further upside here.
In 2029, LPCN is projected to trade between $3.12 and $5.94, averaging $4.15 — a potential gain of +72% from today's $2.41. That is up +9% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Lipocine Inc.'s 2030 outlook centres on $4.29, within a $3.16 to $6.30 range. That is up +3% on the projected 2029 average. That marks a +78% change versus current levels. Momentum favours further upside here.
By 2031, LPCN could reach as high as $7.01, with a base case around $4.68 and support toward $3.38 — roughly +94% from $2.41. Buyers look set to stay in control over this stretch.
Expect LPCN to range from $3.50 to $7.55 through 2032. The $4.94 average target implies a +105% move from current prices. That is up +6% on the projected 2031 average. Momentum favours further upside here.
The LPCN price prediction for 2033 points to an average of $5.66 (low $3.95, high $8.81) — a potential gain of +135% on today's $2.41. Buyers look set to stay in control over this stretch.
In 2034, LPCN is projected to trade between $4.83 and $11.13, averaging $7.04 — a potential gain of +192% from today's $2.41. That is up +24% on the projected 2033 average. Momentum favours further upside here.
Lipocine Inc.'s 2035 outlook centres on $7.56, within a $5.10 to $12.13 range. That is up +7% on the projected 2034 average. That marks a +214% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, LPCN could reach as high as $19.13, with a base case around $11.18 and support toward $7.03 — roughly +364% from $2.41. Momentum favours further upside here.
Expect LPCN to range from $11.26 to $37.98 through 2050. The $20.24 average target implies a +740% move from current prices. That is up +81% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in LPCN today (≈ 414.937759 LPCN) could be worth
$8,398.21
+$7,398.21 (+740%) by 2050 · US Dollar
Based on the average projected LPCN price of $20.24 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LPCNwould be worth at today's price.
$1,000 invested in LPCN on Jul 10, 2025 (≈ 301.204825 LPCN) would be worth
$725.9
-$274.1 (-27.4%) today · 0.73× · US Dollar
Based on a LPCN entry price of $3.32 vs. today's $2.41.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.39 | $1,008.37 | +0.8% |
| 1 month ago | $1.98 | $1,217.17 | +21.7% |
| 3 months ago | $2.2 | $1,095.45 | +9.5% |
| 6 months ago | $9.03 | $266.89 | -73.3% |
| 1 year ago | $3.32 | $725.9 | -27.4% |
| All time (5.0y) ago | $22.95 | $105.01 | -89.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LPCN forecast.
Our base-case forecast reaches $4.80 around 2032.
Implied market cap at $4.80: $39.57M
The multi-year forecast shows a bullish trajectory, with 2026 average at $2.53 and 2030 average at $4.78, then rising to 2040 average of $13.40 and 2050 average of $24.75. The 2030, 2040, and 2050 ROIs are 89.1, 429.5, and 878.2 respectively. These upside paths accompany a progression of averages across successive years, including 2027 average $3.62, 2028 $4.18, 2029 $4.74, 2031 $5.13, 2032 $5.67, 2033 $6.46, 2034 $8.24, and 2035 $9.14.
The forecast also notes bullish sentiment for the long horizon. Drivers of the outlook include Lipocine’s focus on neurological and psychiatric CNS disorders, liver disease, and hormone supplementation. These are estimates and not guarantees, and investing in small biotech equities carries inherent risks.
Tap a question to reveal the answer.
Avg $4.78; Min $3.38; Max $7.35; ROI 89.1; Sentiment BULLISH.
Forecast shows sentiment BULLISH in 2027-2050 with 2027 avg $3.62, 2030 avg $4.78, 2040 avg $13.40, and 2050 avg $24.75; ROI values include 2030 89.1, 2040 429.5, 2050 878.2.
Yes—the 2050 max forecast is $50.35; ROI 878.2.
$2.53 per share.
The 30-day range is $2.01 to $3.18.
Lipocine Inc. Community Discussion
0Share your Lipocine Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.